These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38825840)

  • 1. Magnetic Resonance Imaging Measures to Track Atrophy Progression in Progressive Supranuclear Palsy in Clinical Trials.
    Quattrone A; Franzmeier N; Huppertz HJ; Klietz M; Roemer SN; Boxer AL; Levin J; Höglinger GU;
    Mov Disord; 2024 Jun; ():. PubMed ID: 38825840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal magnetic resonance imaging in progressive supranuclear palsy: A new combined score for clinical trials.
    Höglinger GU; Schöpe J; Stamelou M; Kassubek J; Del Ser T; Boxer AL; Wagenpfeil S; Huppertz HJ; ; ;
    Mov Disord; 2017 Jun; 32(6):842-852. PubMed ID: 28436538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain MRI in Progressive Supranuclear Palsy with Richardson's Syndrome and Variant Phenotypes.
    Wattjes MP; Huppertz HJ; Mahmoudi N; Stöcklein S; Rogozinski S; Wegner F; Klietz M; Apostolova I; Levin J; Katzdobler S; Buhmann C; Quattrone A; Berding G; Brendel M; Barthel H; Sabri O; Höglinger G; Buchert R;
    Mov Disord; 2023 Oct; 38(10):1891-1900. PubMed ID: 37545102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MRI Outperforms [18F]AV-1451 PET as a Longitudinal Biomarker in Progressive Supranuclear Palsy.
    Whitwell JL; Tosakulwong N; Schwarz CG; Botha H; Senjem ML; Spychalla AJ; Ahlskog JE; Knopman DS; Petersen RC; Jack CR; Lowe VJ; Josephs KA
    Mov Disord; 2019 Jan; 34(1):105-113. PubMed ID: 30468693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study.
    Nigro S; Antonini A; Vaillancourt DE; Seppi K; Ceravolo R; Strafella AP; Augimeri A; Quattrone A; Morelli M; Weis L; Fiorenzato E; Biundo R; Burciu RG; Krismer F; McFarland NR; Mueller C; Gizewski ER; Cosottini M; Del Prete E; Mazzucchi S; Quattrone A
    Mov Disord; 2020 Jun; 35(6):976-983. PubMed ID: 32092195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stepwise Functional Brain Architecture Correlates with Atrophy in Progressive Supranuclear Palsy.
    Spinelli EG; Ghirelli A; Bottale I; Basaia S; Canu E; Castelnovo V; Volontè MA; Galantucci S; Magnani G; Caso F; Cecchetti G; Caroppo P; Prioni S; Villa C; Josephs KA; Whitwell JL; Filippi M; Agosta F
    Mov Disord; 2024 Jun; ():. PubMed ID: 38881298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Midbrain atrophy in patients with presymptomatic progressive supranuclear palsy-Richardson's syndrome.
    Ahn JH; Kim M; Kim JS; Youn J; Jang W; Oh E; Lee PH; Koh SB; Ahn TB; Cho JW
    Parkinsonism Relat Disord; 2019 Sep; 66():80-86. PubMed ID: 31307918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brainstem Biomarkers of Clinical Variant and Pathology in Progressive Supranuclear Palsy.
    Grijalva RM; Pham NTT; Huang Q; Martin PR; Ali F; Clark HM; Duffy JR; Utianski RL; Botha H; Machulda MM; Weigand SD; Ahlskog JE; Dickson DW; Josephs KA; Whitwell JL
    Mov Disord; 2022 Apr; 37(4):702-712. PubMed ID: 34970796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tideglusib reduces progression of brain atrophy in progressive supranuclear palsy in a randomized trial.
    Höglinger GU; Huppertz HJ; Wagenpfeil S; Andrés MV; Belloch V; León T; Del Ser T;
    Mov Disord; 2014 Apr; 29(4):479-87. PubMed ID: 24488721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy-Parkinsonism From Parkinson's Disease.
    Quattrone A; Bianco MG; Antonini A; Vaillancourt DE; Seppi K; Ceravolo R; Strafella AP; Tedeschi G; Tessitore A; Cilia R; Morelli M; Nigro S; Vescio B; Arcuri PP; De Micco R; Cirillo M; Weis L; Fiorenzato E; Biundo R; Burciu RG; Krismer F; McFarland NR; Mueller C; Gizewski ER; Cosottini M; Del Prete E; Mazzucchi S; Quattrone A
    Mov Disord; 2022 Jun; 37(6):1272-1281. PubMed ID: 35403258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-Brain Magnetic Resonance Spectroscopy Reveals Distinct Alterations in Neurometabolic Profile in Progressive Supranuclear Palsy.
    Klietz M; Mahmoudi N; Maudsley AA; Sheriff S; Bronzlik P; Almohammad M; Nösel P; Wegner F; Höglinger GU; Lanfermann H; Ding XQ
    Mov Disord; 2023 Aug; 38(8):1503-1514. PubMed ID: 37289057
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal Magnetic Resonance Imaging Quantification of Brain Changes in Progressive Supranuclear Palsy.
    Pyatigorskaya N; Yahia-Cherif L; Gaurav R; Ewenczyk C; Gallea C; Valabregue R; Gargouri F; Magnin B; Degos B; Roze E; Bardinet E; Poupon C; Arnulf I; Vidailhet M; Lehericy S
    Mov Disord; 2020 Jan; 35(1):161-170. PubMed ID: 31710146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Midbrain MRI assessments in progressive supranuclear palsy subtypes.
    Picillo M; Tepedino MF; Abate F; Erro R; Ponticorvo S; Tartaglione S; Volpe G; Frosini D; Cecchi P; Cosottini M; Ceravolo R; Esposito F; Pellecchia MT; Barone P; Manara R
    J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):98-103. PubMed ID: 31527182
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Automated brainstem volumetry can aid in the diagnostics of parkinsonian disorders.
    Sjöström H; Granberg T; Hashim F; Westman E; Svenningsson P
    Parkinsonism Relat Disord; 2020 Oct; 79():18-25. PubMed ID: 32858488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Temporal Progression Patterns of Brain Atrophy in Corticobasal Syndrome and Progressive Supranuclear Palsy Revealed by Subtype and Stage Inference (SuStaIn).
    Saito Y; Kamagata K; Wijeratne PA; Andica C; Uchida W; Takabayashi K; Fujita S; Akashi T; Wada A; Shimoji K; Hori M; Masutani Y; Alexander DC; Aoki S
    Front Neurol; 2022; 13():814768. PubMed ID: 35280291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy of MR markers for differentiating Progressive Supranuclear Palsy from Parkinson's disease.
    Zanigni S; Calandra-Buonaura G; Manners DN; Testa C; Gibertoni D; Evangelisti S; Sambati L; Guarino M; De Massis P; Gramegna LL; Bianchini C; Rucci P; Cortelli P; Lodi R; Tonon C
    Neuroimage Clin; 2016; 11():736-742. PubMed ID: 27330973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rates of brain atrophy and clinical decline over 6 and 12-month intervals in PSP: determining sample size for treatment trials.
    Whitwell JL; Xu J; Mandrekar JN; Gunter JL; Jack CR; Josephs KA
    Parkinsonism Relat Disord; 2012 Mar; 18(3):252-6. PubMed ID: 22079523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal MRI in progressive supranuclear palsy and multiple system atrophy: rates and regions of atrophy.
    Paviour DC; Price SL; Jahanshahi M; Lees AJ; Fox NC
    Brain; 2006 Apr; 129(Pt 4):1040-9. PubMed ID: 16455792
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tracking brain damage in progressive supranuclear palsy: a longitudinal MRI study.
    Agosta F; Caso F; Ječmenica-Lukić M; Petrović IN; Valsasina P; Meani A; Copetti M; Kostić VS; Filippi M
    J Neurol Neurosurg Psychiatry; 2018 Jul; 89(7):696-701. PubMed ID: 29348302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification.
    Huppertz HJ; Möller L; Südmeyer M; Hilker R; Hattingen E; Egger K; Amtage F; Respondek G; Stamelou M; Schnitzler A; Pinkhardt EH; Oertel WH; Knake S; Kassubek J; Höglinger GU
    Mov Disord; 2016 Oct; 31(10):1506-1517. PubMed ID: 27452874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.